



May 14, 2026

Ref:- GHL/2026-27/EXCH/09

The General Manager  
Dept. of Corporate Services  
BSE Limited,  
P J Towers, Dalal Street,  
Mumbai - 400 001

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

**Sub:** Outcome of Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (*'Listing Regulations'*)

Dear Sir(s),

We would like to inform you that the Board of Directors of Global Health Limited (**'GHL/Company'**) at its meeting held today i.e. *Thursday, May 14, 2026*, has *inter alia*, approved the following:


1. Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and financial year ended March 31, 2026 (**'Results'**);

The certified copies of Results along with Audit Reports the Statutory Auditors M/s Walker Chandio & Co LLP, Chartered Accountants thereon, are enclosed herewith as **Annexure I**, pursuant to Regulation 33 of the Listing Regulations.

Further, in terms of requirements of Regulation 33(3)(d), we hereby confirm you that the aforesaid Audit Report of the Statutory Auditors is Unmodified and contains no audit qualifications.

2. Recommendation of Final Dividend of Rs. 0.50/- (25%) per Equity Share of face value of Rs. 2/- each for the Financial Year ended March 31, 2026, subject to approval of the Shareholders at the ensuing Annual General Meeting (AGM) of the Company. The Record Date for confirming the eligibility of Shareholders shall be intimated separately.

Further, the said Final Dividend, if declared by the Shareholders at the ensuing AGM shall be paid/ despatched to all eligible shareholders within 30 days from the date of AGM.





3. Appointment of Mr. Kedar Ashok Apte designated as 'Chief Marketing & Growth Officer' and Mr. Jagdeep Singh designated as 'General Counsel' and as SMPs of the Company basis the recommendation of Nomination and Remuneration Committee w.e.f. May 14, 2026.
4. Noted the resignation of Ms. Richa Singh one of the SMP of the Company w.e.f. May 20, 2026.

The details as required under Regulation 30 of SEBI Listing Regulations, 2015 read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed as **Annexure II**.

The Trading Window will open after 48 hours from the declaration of above Results, to the Stock Exchanges.


The meeting of the Board of Directors commenced at 02.00 P.M. and concluded at 04:10 P.M.

Thanking You,

**For Global Health Limited**

**Rahul Ranjan**  
**Company Secretary & Compliance Officer**  
**M. No. A17035**

**Encl: a/a**



# Walker Chandio & Co LLP

Walker Chandio & Co LLP  
21st Floor, DLF Square  
Jacaranda Marg, DLF Phase II  
Gurugram - 122 002  
India

T +91 124 462 8099  
F +91 124 462 8001

## Independent Auditor's Report on Standalone Annual Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Global Health Limited

### Opinion

1. We have audited the accompanying standalone annual financial results ('the Statement') of Global Health Limited ('the Company') which includes GHLEmployee Welfare Trust ('the Trust') for the year ended 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
  - (i) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations; and
  - (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under section 133 of the Companies Act, 2013 ('the Act'), read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company for the year ended 31 March 2026.

### Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandio & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India



# Walker Chandio & Co LLP

**Independent Auditor's Report on Standalone Annual Financial Results of Global Health Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)**

## **Responsibilities of Management and Those Charged with Governance for the Statement**

4. This Statement has been prepared on the basis of the standalone annual financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the Ind AS specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
5. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
6. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

## **Auditor's Responsibilities for the Audit of the Statement**

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing, specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
  - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place an adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls;
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;

Chartered Accountants





# Walker Chandiok & Co LLP

## Independent Auditor's Report on Standalone Annual Financial Results of Global Health Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
  - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
9. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

### Other Matter

11. The Statement includes the financial results for the quarter ended 31 March 2026, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

### For Walker Chandiok & Co LLP

Chartered Accountants

Firm Registration No.: 001076N/N500013




**Tarun Gupta**

Partner

Membership No. 507892

UDIN: 26507892VMDFQI6566



**Place:** Gurugram

**Date:** 14 May 2026

**Global Health Limited**  
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India  
Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India  
CIN:L85110DL2004PLC128319  
Tel: +91 124 483 4060; E-mail: [compliance@medanta.org](mailto:compliance@medanta.org); Website: <https://www.medanta.org>  
Statement of standalone financial results for the quarter and year ended 31 March 2026

S No.	Particulars	(₹ in millions, unless otherwise stated)				
		Quarter ended			Year ended	
		31 March 2026 (Refer note 11)	31 December 2025 Unaudited	31 March 2025 (Refer note 11)	31 March 2026 Audited	31 March 2025 Audited
	<b>Income</b>					
I	Revenue from operations	9,606.29	9,401.65	8,028.68	37,093.78	32,041.46
II	Other income	358.05	246.64	256.66	1,064.08	908.09
	<b>Total income</b>	<b>9,964.34</b>	<b>9,648.29</b>	<b>8,285.34</b>	<b>38,157.86</b>	<b>32,949.55</b>
III	<b>Expenses</b>					
	Cost of materials consumed	1,886.44	2,018.33	1,723.75	7,858.56	7,158.13
	Purchases of stock-in-trade	(0.05)	(5.67)	58.23	19.43	403.90
	Changes in inventories of stock-in-trade	-	5.98	32.07	46.11	26.24
	Employee benefits expense	2,556.81	2,523.00	1,854.16	9,892.59	7,462.91
	Finance costs	134.64	130.80	70.99	410.85	333.91
	Depreciation and amortisation expense	522.08	478.63	379.80	1,709.07	1,496.11
	Retainers and consultants fee	1,559.40	1,510.78	1,064.64	5,445.32	4,038.72
	Other expenses	1,670.27	1,605.58	1,343.87	6,283.16	5,300.20
	<b>Total expenses</b>	<b>8,329.59</b>	<b>8,267.43</b>	<b>6,527.51</b>	<b>31,665.09</b>	<b>26,220.12</b>
IV	<b>Profit before exceptional items and tax</b>	<b>1,634.75</b>	<b>1,380.86</b>	<b>1,757.83</b>	<b>6,492.77</b>	<b>6,729.43</b>
	Exceptional items (refer note 6)	-	352.00	498.96	(3.77)	498.96
V	<b>Profit before tax</b>	<b>1,634.75</b>	<b>1,028.86</b>	<b>1,258.87</b>	<b>6,496.54</b>	<b>6,230.47</b>
VI	<b>Tax expenses</b>					
	Current tax	326.31	247.52	361.77	1,345.72	1,608.65
	Tax pertaining to earlier years	(7.85)	(25.45)	6.88	(33.30)	6.88
	Deferred tax charge/(credit)	74.98	7.72	(43.90)	222.11	(0.34)
VII	<b>Profit after tax</b>	<b>1,241.31</b>	<b>799.07</b>	<b>934.12</b>	<b>4,962.01</b>	<b>4,615.28</b>
VIII	<b>Other comprehensive income</b>					
	(i) Items that will not be reclassified to statement of profit or loss	47.94	6.36	(30.20)	46.64	(12.94)
	(ii) Equity instruments through OCI	(1.60)	-	-	(1.60)	-
	(iii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(12.07)	(1.60)	7.60	(11.74)	3.26
	<b>Total other comprehensive income</b>	<b>34.27</b>	<b>4.76</b>	<b>(22.60)</b>	<b>33.30</b>	<b>(9.68)</b>
IX	<b>Total comprehensive income</b>	<b>1,275.58</b>	<b>803.83</b>	<b>911.52</b>	<b>4,995.31</b>	<b>4,605.60</b>
X	Paid-up equity share capital (face value of ₹ 2 each)	537.38	537.58	537.17	537.38	537.17
XI	Reserves (other equity)				39,588.28	34,438.91
XII	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters)					
	Basic (₹ per share)	4.62	2.97	3.48	18.46	17.18
	Diluted (₹ per share)	4.61	2.97	3.48	18.42	17.18

See accompanying notes to the audited standalone financial results





Global Health Limited  
CIN: L85110DL2004PLC128319

Note 1: Standalone balance sheet as at 31 March 2026

(₹ in millions, unless otherwise stated)

Particulars	As at	As at
	31 March 2026	31 March 2025
	Audited	Audited
<b>ASSETS</b>		
Property, plant and equipment	23,404.48	14,663.01
Right-of-use assets	5,489.10	3,896.17
Capital work-in-progress	1,197.01	4,535.46
Intangible assets	137.85	48.55
Intangible assets under development	0.59	41.71
Financial assets		
Investments	3,893.68	3,655.08
Loans	1,436.30	1,568.59
Other financial assets	1,047.92	262.95
Deferred tax assets (net)	43.06	140.79
Income-tax assets (net)	356.40	598.61
Other non-current assets	804.88	467.41
<b>Total non-current assets</b>	<b>37,811.27</b>	<b>29,878.33</b>
<b>Current assets</b>		
Inventories	508.97	489.95
Financial assets		
Trade receivables	3,868.53	2,915.86
Cash and cash equivalents	959.08	1,900.65
Bank balances other than cash and cash equivalents	9,804.50	8,627.16
Loans	103.55	145.87
Other financial assets	286.48	286.58
Other current assets	172.31	161.45
<b>Total current assets</b>	<b>15,703.42</b>	<b>14,527.52</b>
<b>Total assets</b>	<b>53,514.69</b>	<b>44,405.85</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	537.38	537.17
Other equity	39,588.28	34,438.91
<b>Total equity</b>	<b>40,125.66</b>	<b>34,976.08</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
Borrowings	4,492.02	1,143.09
Lease liabilities	2,048.62	1,779.01
Other financial liabilities	-	477.08
Provisions	1,085.45	633.26
Other non-current liabilities	451.80	209.08
<b>Total non-current liabilities</b>	<b>8,077.89</b>	<b>4,241.52</b>
<b>Current liabilities</b>		
Financial liabilities		
Borrowings	87.05	261.33
Lease liabilities	198.90	188.46
Trade payables		
Total outstanding dues of micro enterprises and small enterprises	729.49	711.76
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,291.41	975.06
Other financial liabilities	1,198.52	1,145.21
Other current liabilities	1,515.04	1,470.88
Provisions	290.73	435.55
<b>Total current liabilities</b>	<b>5,311.14</b>	<b>5,188.25</b>
<b>Total equity and liabilities</b>	<b>53,514.69</b>	<b>44,405.85</b>



## Global Health Limited

CIN: L85110DL2004PLC128319

Note 2: Standalone Statement of Cash Flow for the year ended 31 March 2026

(₹ in millions, unless otherwise stated)

Particulars	For the year ended 31 March 2026	For the year ended 31 March 2025
	Audited	Audited
<b>A CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit before tax	6,496.54	6,230.47
<b>Adjustments for:</b>		
Exceptional items	(3.77)	498.96
Depreciation and amortisation expense	1,709.07	1,496.11
Gain on disposal of property, plant and equipments (net)	(0.76)	(2.04)
Gain on de-recognition of lease liabilities and right of use assets	-	(0.27)
Liabilities written back	(41.69)	(45.50)
Grant income (on account of government and other grants)	(551.16)	(160.46)
Interest income	(973.62)	(813.12)
Unrealised foreign exchange loss/(gain) (net)	3.96	(3.67)
Finance costs	410.85	333.91
Provision/Bad debts written-off on trade receivables and other financial assets	95.52	189.59
Assets written off	0.68	-
Employee share based payment expense	368.57	-
(Reversal)/provision for contingencies	(5.23)	59.26
<b>Operating profit before working capital changes</b>	<b>7,508.96</b>	<b>7,783.24</b>
<b>Movement in working capital:</b>		
Inventories	(19.02)	63.55
Trade receivables	(1,049.90)	(948.87)
Other assets	(59.06)	(105.65)
Other liabilities	57.37	(153.03)
Trade payables	372.15	114.05
Provisions	7.24	130.78
<b>Cash flows from operating activities</b>	<b>6,817.74</b>	<b>6,884.07</b>
Income-tax paid (net)	(1,084.57)	(1,607.41)
<b>Net cash flows generated from operating activities (A)</b>	<b>5,733.17</b>	<b>5,276.66</b>
<b>B CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of property plant and equipments, capital work-in-progress and intangible assets (including capital advances, capital creditors and deferred payment liabilities)	(6,755.57)	(4,276.89)
Payment for acquisition of land	(1,403.97)	(1,313.70)
Proceeds from disposal of property, plant and equipments	2.98	23.13
Movement in other bank balances and bank deposits (net)	(1,984.66)	(1,199.15)
Interest received	893.28	788.14
Investment in subsidiary companies	(240.20)	-
Investment in equity shares	-	(39.10)
Loan to subsidiaries	-	(450.00)
Loans repayment from subsidiaries (net)	174.62	85.54
<b>Net cash used in investing activities (B)</b>	<b>(9,313.52)</b>	<b>(6,382.03)</b>
<b>C CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from issue of equity share capital (net of share issue expenses)	0.21	0.16
Purchase of treasury shares	(98.24)	-
Proceeds from borrowings	-	1,150.00
Proceeds from non-current borrowings	3,452.12	-
Repayment of borrowings	-	(1,718.57)
Dividend paid (including tax)	(134.40)	-
Interest paid on borrowings	(250.30)	(114.96)
Payment of interest on lease payments	(213.19)	(168.44)
Principal elements of lease liabilities	(117.42)	(93.10)
<b>Net cash flows generated from/ (used in) financing activities (C)</b>	<b>2,638.78</b>	<b>(944.91)</b>
<b>Net decrease in cash and cash equivalents (A+B+C)</b>	<b>(941.57)</b>	<b>(2,050.28)</b>
Cash and cash equivalents at the beginning of the year	1,900.65	3,950.93
<b>Cash and cash equivalents at the end of the period</b>	<b>959.08</b>	<b>1,900.65</b>
<b>Reconciliation of cash and cash equivalents as per statement of cash flow</b>		
Balances with banks in current accounts	342.82	591.71
Cheques on hand	0.07	0.34
Cash on hand	36.19	28.60
Bank deposits with original maturity less than three months	580.00	1,280.00
	<b>959.08</b>	<b>1,900.65</b>





**Global Health Limited**
**Notes to the standalone audited financial results (cont'd):**

- 3 The above standalone financial results of Global Health Limited ('the Company') for the quarter and year ended on 31 March 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14 May 2026. These standalone financial results for the year ended 31 March 2026 have been audited by statutory auditors.
- 4 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
- 5 The Chief Operating Decision Maker (CODM) examines the Company's performance from a service perspective and has identified the healthcare services as single business segment.
- 6 **Exceptional items include:**

Particulars	Quarter ended		Year ended	
	31 December 2025	31 March 2025	31 March 2026	31 March 2025
Export Promotion Capital Goods (EPCG) obligation (Refer point a below)	-	-	(195.92)	-
Stamp duty on merger (Refer point b below)	-	498.96	(159.85)	498.96
Impact of new labour codes (Refer point c below)	352.00	-	352.00	-
<b>Total</b>	<b>352.00</b>	<b>498.96</b>	<b>(3.77)</b>	<b>498.96</b>

- a During the quarter ended 30 June 2025, the Company reversed interest liability on EPCG amounting to ₹ 195.92 millions. Pursuant to the filing of merger order with Registrar of Companies (ROC), the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Company. The Company has achieved the required export obligation within the prescribed timeline.
- b During the year ended 31 March 2025, stamp duty was payable in connection with the merger of Medanta Holdings Private Limited with the Company. Subsequently, during the quarter ended 30 September 2025, the Company reversed stamp duty amounting to ₹ 159.85 millions payable to Government of National Capital Territory of Delhi, pursuant to adjudication of its stamp duty application.
- c On 21 November 2025, the Government of India notified the four Labour Codes—namely, the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020—thereby consolidating 29 existing labour laws. To facilitate the assessment of the financial impact arising from these regulatory changes, the Ministry of Labour & Employment issued Central Rules and related FAQs.

The Company has evaluated and disclosed the incremental impact of these changes based on expert input and the best information available, in line with the guidance provided by the Institute of Chartered Accountants of India. Given the material, regulatory-driven, and non-recurring nature of this impact, the Company has presented such incremental impact, aggregating to ₹352.00 millions under 'Exceptional items'.

The Company continues to monitor the finalisation of the Central and State Rules and any further government clarifications on other aspects of the Labour Codes, and will record the accounting treatment as required based on future developments.

- 7a During the quarter ended 31 March 2026, the company executed a definitive agreement to enter into a built-to-suit and lease arrangement with Shripal Hospitality LLP & others for 400 bed multi-speciality hospital in Varanasi, Uttar Pradesh.
- 7b Subsequent to year ended 31 March 2026, the Company executed a Business Transfer Agreement (BTA) with Asian Institute of Oncology Private Limited for a 79 bedded Advanced Super Speciality Hospital primarily engaged in providing oncology services in Indore.
- 8 During the year ended 31 March 2026, the Board of Directors of the Company has approved the grant of 619,500 Options to certain eligible employees and allotted 183,000 shares to GHIL Employees Welfare Trust under Part -A and Part- B respectively of Global Health Limited Employees Long-Term Share Based Incentive Plan – 2024.

**Employee benefits expense includes:**

Particulars	Quarter ended			Year ended	
	31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
Employee share based payment expense	96.98	100.15	-	368.57	-

- 9 The Board of Directors of the Company proposed a final dividend of ₹ 0.50/- per equity share of ₹ 2/- each fully paid up, subject to approval in the ensuing annual general meeting.
- 10 The standalone financial results also include the financial statements of GHIL Employee Welfare Trust.
- 11 The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures for the full financial year and the unaudited figures up to the nine months ended 31 December 2025 and 31 December 2024, respectively, which were subjected to limited review by the statutory auditors.
- 12 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

**For and on behalf of the Board of Directors of Global Health Limited**

Place : Gurugram  
Date : 14 May 2026



  
**Dr. Naresh Trehan**  
Chairman and Managing Director



**Independent Auditor's Report on Consolidated Annual Financial Results of Global Health Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)**

**To the Board of Directors of Global Health Limited**

**Opinion**

1. We have audited the accompanying consolidated annual financial results ('the Statement') of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), for the year ended 31 March 2026, attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
  - (i) includes the annual financial results of the entities listed in Annexure 1;
  - (ii) presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations; and
  - (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the consolidated net profit after tax and other comprehensive income and other financial information of the Group, for the year ended 31 March 2026.

**Basis for Opinion**

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Group, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the consolidated financial results under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

**Responsibilities of Management and Those Charged with Governance for the Statement**

4. The Statement has been prepared on the basis of the consolidated annual financial statements and has been approved by the Holding Company's Board of Directors. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit and other comprehensive income, and other financial information of the Group in accordance with the Ind AS prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Holding Company's Board of Directors is also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of the Statement. Further, in terms of the provisions of the Act, the respective Board of Directors of the companies included in the Group, covered under the Act, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group, and for preventing and detecting frauds and other irregularities; selection

Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Goa, Gurugram, Hyderabad, Indore, Kochi, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker Chandiook & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India





# Walker Chandio & Co LLP

## Independent Auditor's Report on Consolidated Annual Financial Results of Global Health Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

5. In preparing the Statement, the respective Board of Directors of the companies included in the Group, are responsible for assessing the ability of the Group, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
6. Those respective Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group.

### Auditor's Responsibilities for the Audit of the Statement

7. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error, and are considered material if, individually, or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
8. As part of an audit in accordance with the Standards on Auditing specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
  - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
  - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls;
  - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors;
  - Conclude on the appropriateness of Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group, to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern;
  - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation; and
  - Obtain sufficient appropriate audit evidence regarding the financial statements of the entities or business activities within the Group, to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Statement, of which we are the independent auditors.

Chartered Accountants



# Walker Chandiok & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of Global Health Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

9. We communicate with those charged with governance of the Holding Company regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
10. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## Other Matter

11. The Statement includes the consolidated financial results for the quarter ended 31 March 2026, being the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year-to-date consolidated figures up to the third quarter of the current financial year, which were subject to limited review by us.

For Walker Chandiok & Co LLP  
Chartered Accountants  
Firm Registration No.: 001076N/N500013



Tarun Gupta  
Partner  
Membership No. 507892  
UDIN: 26507892IXTYCY6760



Place: Gurugram  
Date: 14 May 2026



# Walker ChandioK & Co LLP

Independent Auditor's Report on Consolidated Annual Financial Results of Global Health Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

## Annexure 1

### List of entities included in the Statement

S. No.	Name	Relationship with Holding Company
1	Global Health Patliputra Private Limited	Wholly owned subsidiary
2	GHL Pharma & Diagnostic Private Limited	Wholly owned subsidiary
3	GHL Hospital Limited	Subsidiary
4	Global Health Institute of Medical Sciences Foundation	Wholly owned subsidiary
5	Medanta Foundation - Poor and Needy Patients Welfare Trust	Trust



**Global Health Limited**  
Registered Office: Medanta Mediclinic, E-18, Defence Colony, New Delhi - 110024, India  
Corporate Office: Medanta – The Medicity, Sector – 38, Gurgaon, Haryana - 122001, India  
CIN: L85110DL2004PLC128319  
Tel: +91 124 483 4060; E-mail: [compliance@medanta.org](mailto:compliance@medanta.org); Website: <https://www.medanta.org>  
Statement of consolidated financial results for the quarter and year ended 31 March 2026

(₹ in millions, unless otherwise stated)						
S. No.	Particulars	Quarter ended			Year ended	
		31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
		(Refer note 10)	Unaudited	(Refer note 10)	Audited	Audited
	<b>Income</b>					
I	Revenue from operations	11,590.47	11,210.94	9,312.52	44,102.66	36,923.45
II	Other income	367.42	217.35	229.25	985.94	789.47
	<b>Total income</b>	<b>11,957.89</b>	<b>11,428.29</b>	<b>9,541.77</b>	<b>45,088.60</b>	<b>37,712.92</b>
III	<b>Expenses</b>					
	Cost of materials consumed	2,156.47	2,267.15	1,914.79	8,821.31	7,899.60
	Purchases of stock-in-trade	277.98	289.28	205.11	1,173.00	924.61
	Changes in inventories of stock-in-trade	30.84	0.16	16.29	(26.30)	(27.52)
	Employee benefits expense	2,846.97	2,806.73	2,040.54	10,961.08	8,245.42
	Finance costs	267.08	215.09	150.30	791.14	652.59
	Depreciation and amortisation expense	665.18	611.88	492.54	2,225.40	1,937.48
	Retainers and consultants fee	1,869.28	1,793.95	1,315.92	6,579.68	4,973.43
	Other expenses	1,971.30	1,880.24	1,572.94	7,402.91	6,135.78
	<b>Total expenses</b>	<b>10,085.10</b>	<b>9,864.48</b>	<b>7,708.43</b>	<b>37,928.22</b>	<b>30,741.39</b>
IV	<b>Profit before exceptional items and tax</b>	<b>1,872.79</b>	<b>1,563.81</b>	<b>1,833.34</b>	<b>7,160.38</b>	<b>6,971.53</b>
	Exceptional items (refer note 6)	-	365.98	498.96	10.21	498.96
V	<b>Profit before tax</b>	<b>1,872.79</b>	<b>1,197.83</b>	<b>1,334.38</b>	<b>7,150.17</b>	<b>6,472.57</b>
VI	<b>Tax expenses</b>					
	Current tax	326.31	247.52	361.77	1,345.72	1,608.65
	Tax pertaining to earlier years	(7.85)	(25.45)	6.88	(33.30)	6.88
	Deferred tax charge/(credit)	137.80	25.43	(48.05)	297.07	43.86
VII	<b>Profit after tax</b>	<b>1,416.53</b>	<b>950.33</b>	<b>1,013.78</b>	<b>5,540.68</b>	<b>4,813.18</b>
VIII	<b>Other comprehensive income</b>					
	(i) Items that will not be reclassified to statement of profit or loss	51.81	8.28	(30.46)	50.86	(9.13)
	(ii) Equity instruments through OCI	(1.60)	-	-	(1.60)	-
	(iii) Income-tax relating to items that will not be reclassified to statement of profit or loss	(13.06)	(2.08)	7.72	(12.81)	2.43
	<b>Total other comprehensive income</b>	<b>37.15</b>	<b>6.20</b>	<b>(22.74)</b>	<b>36.45</b>	<b>(6.70)</b>
IX	<b>Total comprehensive income</b>	<b>1,453.68</b>	<b>956.53</b>	<b>991.04</b>	<b>5,577.13</b>	<b>4,806.48</b>
	<b>Profit after tax attributable to:</b>					
	(i) Owners of the Holding Company	1,439.88	950.22	1,014.00	5,564.60	4,814.37
	(ii) Non-controlling interests	(23.35)	0.11	(0.22)	(23.92)	(1.19)
	<b>Other comprehensive income attributable to:</b>					
	(i) Owners of the Holding Company	37.14	6.20	(22.74)	36.44	(6.70)
	(ii) Non-controlling interests	0.01	-	-	0.01	-
	<b>Total comprehensive income attributable to:</b>					
	(i) Owners of the Holding Company	1,477.02	956.42	991.26	5,601.04	4,807.67
	(ii) Non-controlling interests	(23.34)	0.11	(0.22)	(23.91)	(1.19)
X	Paid-up equity share capital (face value of ₹ 2 each)	537.38	537.58	537.17	537.38	537.17
XI	Reserves (other equity)				39,078.32	33,326.93
XII	Earnings per share (face value of ₹ 2 each) (not annualised for the quarters)					
	Basic (₹ per share)	5.36	3.54	3.77	20.71	17.92
	Diluted (₹ per share)	5.35	3.54	3.77	20.66	17.92

See accompanying notes to the audited consolidated financial results





(₹ in millions, unless otherwise stated)

Particulars	As at	As at
	31 March 2026	31 March 2025
	Audited	Audited
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	29,623.44	19,752.64
Right-of-use assets	8,163.70	5,322.74
Capital work-in-progress	1,322.05	5,285.21
Intangible assets	160.46	64.69
Intangible assets under development	1.57	48.16
Financial assets		
Investments	25.50	27.10
Other financial assets	1,116.88	300.48
Deferred tax assets (net)	156.46	330.23
Income-tax assets (net)	554.78	687.18
Other non-current assets	1,176.00	512.64
<b>Total non-current assets</b>	<b>42,300.84</b>	<b>32,331.07</b>
<b>Current assets</b>		
Inventories	789.83	671.41
Financial assets		
Trade receivables	4,111.85	2,918.56
Cash and cash equivalents	1,273.33	2,302.00
Bank balances other than cash and cash equivalents	10,028.95	8,921.35
Other financial assets	321.59	327.98
Other current assets	223.65	189.93
<b>Total current assets</b>	<b>16,749.20</b>	<b>15,331.23</b>
<b>Total assets</b>	<b>59,050.04</b>	<b>47,662.30</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity share capital	537.38	537.17
Other equity	39,078.32	33,326.93
Non-controlling interests	227.05	10.97
<b>Total equity</b>	<b>39,842.75</b>	<b>33,875.07</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
Financial liabilities		
Borrowings	6,011.16	2,641.00
Lease liabilities	5,259.41	3,594.06
Other financial liabilities	3.39	481.16
Provisions	1,139.21	661.68
Other non-current liabilities	522.81	221.16
<b>Total Non-current liabilities</b>	<b>12,935.98</b>	<b>7,599.06</b>
Financial liabilities		
Borrowings	299.59	637.83
Lease liabilities	330.30	304.43
Trade payables		
Total outstanding dues of micro enterprises and small enterprises	879.25	793.65
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,544.45	1,154.47
Other financial liabilities	1,332.28	1,311.97
Other current liabilities	1,585.57	1,511.84
Provisions	299.87	473.98
<b>Total current liabilities</b>	<b>6,271.31</b>	<b>6,188.17</b>
<b>Total equity and liabilities</b>	<b>59,050.04</b>	<b>47,662.30</b>



## Global Health Limited

CIN:L85110DL2004PLC128319

Note 2: Consolidated statement of cash flow for the year ended 31 March 2026

Particulars	(₹ in millions, unless otherwise stated)	
	For the year ended 31 March 2026	For the year ended 31 March 2025
	Audited	Audited
<b>A CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Profit before tax	7,150.17	6,472.57
<b>Adjustments for:</b>		
Exceptional items	10.21	498.96
Depreciation and amortisation expense	2,225.40	1,937.48
Gain on sale of property, plant and equipments (net)	(0.79)	(2.19)
Gain on de-recognition of lease liabilities and right of use assets	(1.81)	(0.27)
Liabilities written back	(77.68)	(45.50)
Grants income (on account of government and other grants)	(558.36)	(161.65)
Interest income	(859.15)	(703.18)
Unrealised foreign exchange loss (net)	25.57	(3.70)
Finance costs	791.14	652.59
Provision/Bad debts written-off on trade receivables and other financial assets	107.85	192.25
Employee share based payment expense	382.98	-
(Reversal)/provision for contingencies	(5.23)	39.64
<b>Operating profit before working capital changes</b>	<b>9,190.30</b>	<b>8,877.00</b>
<b>Movement in working capital:</b>		
Inventories	(118.42)	(2.91)
Trade receivables	(1,302.78)	(949.07)
Other assets	(98.04)	(126.89)
Other liabilities	137.82	(188.77)
Trade payables	535.68	125.88
Provisions	(6.46)	144.71
<b>Cash flows from operating activities</b>	<b>8,338.10</b>	<b>7,879.95</b>
Income-tax paid (net)	(1,194.19)	(1,642.36)
<b>Net cash flows generated from operating activities (A)</b>	<b>7,143.91</b>	<b>6,237.59</b>
<b>B CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of property, plant and equipments, capital work-in-progress and intangible assets (including capital advances, capital creditors and deferred payment liabilities)	(8,381.90)	(5,165.45)
Payment for acquisition of land	(1,403.97)	(1,313.70)
Proceeds from disposal of property, plant and equipments	8.47	29.94
Movement in other bank balances and deposits (net)	(1,889.35)	(1,405.34)
Interest received	775.64	671.74
Investment in equity shares	-	(26.60)
<b>Net cash flows used in investing activities (B)</b>	<b>(10,891.11)</b>	<b>(7,209.41)</b>
<b>C CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from issue of equity share capital	0.21	0.16
Proceeds from issue of equity share capital to non-controlling interest	240.00	12.50
Purchase of treasury shares	(98.24)	-
Proceeds from borrowings	3,686.64	1,491.65
Repayment of borrowings	(121.15)	(1,834.27)
Dividend paid	(134.40)	-
Interest paid on borrowings	(387.67)	(252.79)
Payment of interest on lease payments	(336.41)	(284.01)
Principal elements of lease liabilities	(130.45)	(105.50)
<b>Net cash flows generated from/ (used in) financing activities (C)</b>	<b>2,718.53</b>	<b>(972.26)</b>
<b>Net decrease in cash and cash equivalents (A+B+C)</b>	<b>(1,028.67)</b>	<b>(1,944.08)</b>
Cash and cash equivalents at the beginning of the year	2,302.00	4,246.08
<b>Cash and cash equivalents at the end of the year</b>	<b>1,273.33</b>	<b>2,302.00</b>
<b>Reconciliation of cash and cash equivalents as per statement of cash flow</b>		
Balances with banks in current accounts	420.03	784.45
Cheques on hand	0.07	0.62
Cash on hand	48.03	35.19
Bank deposits with original maturity less than three months	805.20	1,481.74
	<b>1,273.33</b>	<b>2,302.00</b>





**Global Health Limited**
**Notes to the consolidated audited financial results:**

- 3 The above consolidated financial results of Global Health Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred as 'the Group'), for the quarter and year ended 31 March 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14 May 2026. These consolidated financial results for the year ended 31 March 2026 have been audited by the statutory auditors.
- 4 These results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act 2013 (the 'Act') read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) and other accounting principles generally accepted in India and is in compliance with presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (as amended).
- 5 The Chief Operating Decision Maker (CODM) examines the Group's performance from a service perspective and has identified the healthcare services as single business segment.

**6 Exceptional items include:**
**(₹ in millions)**

Particulars	Quarter ended		Year ended	
	31 December 2025	31 March 2025	31 March 2026	31 March 2025
Export Promotion Capital Goods (EPCG) Obligation (Refer point a below)	-	-	(195.92)	-
Stamp duty on merger (Refer point b below)	-	498.96	(159.85)	498.96
Impact of new Labour Codes (Refer point c below)	365.98	-	365.98	-
<b>Total</b>	<b>365.98</b>	<b>498.96</b>	<b>10.21</b>	<b>498.96</b>

- a During the quarter ended 30 June 2025, the Holding Company reversed interest liability on Export Promotion Capital Goods (EPCG) amounting to ₹ 195.92 millions. Pursuant to the filing of merger order with Registrar of Companies (ROC), the EPCG licenses have been transferred from Medanta Holdings Private Limited to the Holding Company. The Holding Company has achieved the required export obligation within the prescribed timeline.
- b During the year ended 31 March 2025, stamp duty was payable in connection with the merger of Medanta Holdings Private Limited with the Holding Company. Subsequently, during the quarter ended 30 September 2025, the Holding Company reversed stamp duty amounting to ₹ 159.85 millions payable to Government of National Capital Territory of Delhi, pursuant to adjudication of its stamp duty application.
- c On 21 November 2025, the Government of India notified the four Labour Codes—namely, the Code on Wages, 2019; the Industrial Relations Code, 2020; the Code on Social Security, 2020; and the Occupational Safety, Health and Working Conditions Code, 2020—thereby consolidating 29 existing labour laws. To facilitate the assessment of the financial impact arising from these regulatory changes, the Ministry of Labour & Employment issued Central Rules and related FAQs.

The Group has evaluated and disclosed the incremental impact of these changes based on expert input and the best information available, in line with the guidance provided by the Institute of Chartered Accountants of India. Given the material, regulatory-driven, and non-recurring nature of this impact, the Group has presented such incremental impact, aggregating to ₹365.98 millions under 'Exceptional items'.

The Group continues to monitor the finalisation of the Central and State Rules and any further government clarifications on other aspects of the Labour Codes, and will record the accounting treatment as required based on future developments.

- 7 a During the quarter ended 31 March 2026, the Holding Company executed a definitive agreement to enter into a built-to-suit and lease arrangement with Shripal Hospitality LLP & others for 400 bed multi-speciality hospital in Varanasi, Uttar Pradesh.
- 7 b Subsequent to year ended 31 March 2026, the Holding Company executed a Business Transfer Agreement (BTA) with Asian Institute of Oncology Private Limited for a 79 bedded Advanced Super Speciality Hospital primarily engaged in providing oncology services in Indore.
- 8 During the year ended 31 March 2026, the Board of Directors of the Holding Company has approved the grant of 619,500 Options to certain eligible employees and allotted 183,000 shares to GHL Employees Welfare Trust under Part -A and Part- B respectively of Global Health Limited Employees Long-Term Share Based Incentive Plan – 2024.

**Employee benefits expense includes:**
**(₹ in millions)**

Particulars	Quarter ended			Year ended	
	31 March 2026	31 December 2025	31 March 2025	31 March 2026	31 March 2025
Employee share based payment expense	101.02	103.15	-	382.98	-

- 9 The Board of Directors of the Holding Company proposed a final dividend of ₹ 0.50/- per equity share of ₹ 2/- each fully paid up, subject to approval in the ensuing annual general meeting.
- 10 The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures for the full financial year and the unaudited figures up to the nine months ended 31 December 2025 and 31 December 2024, respectively, which were subjected to limited review by the statutory auditors.
- 11 Previous period figures have been regrouped/reclassified to conform to the current period's classification.

**For and on behalf of the Board of Directors of Global Health Limited**

Place : Gurugram  
Date : 14 May 2026






*Dr. Naresh Trehan*  
**Dr. Naresh Trehan**  
Chairman and Managing Director

**Annexure II**

**Disclosure as mandated under Part- A (Para A) of Schedule III of Listing Regulations:**

**A. Appointments:**


S. No.	Particulars	Details	Details
1.	Reason for change viz. appointment, <del>resignation, removal, death or otherwise</del>	Appointment	Appointment
2.	Date of appointment/ <del>re-appointment/cessation</del> (as applicable) & term of appointment	Mr. Kedar Ashok Apte joined the Company on April 01, 2026 and designated as SMP w.e.f. May 14, 2026.  He will be in full time employment with the Company.	Mr. Jagdeep Singh joined the Company on May 04, 2026 and designated as SMP w.e.f. May 14, 2026.  He will be in full time employment with the Company
3.	Brief profile (in case of appointment)	Mr. Apte has over 23 years of experience with 3 reputed organizations: Unilever, BP/Castrol and Mahindra. He has diverse experience from Beauty, Energy and Retail sector in delivering excellence in customer experience, building strong brands and distribution to deliver strong business performance.	Mr. Jagdeep Singh has over 18 years of experience across group-level legal, compliance and governance functions in large multinational organizations like Vedanta, Hindustan Unilever Limited, BluSmart and Ibibo. His expertise spans Litigation and regulatory matters, Compliance, governance, Contract management and legal process transformation, M&A, restructurings and capital markets transactions.
4.	Disclosure of relationships between directors (in case of appointment of a director)	NA	NA





## B. Resignation:

S. No.	Particulars	Details
1.	Reason for change viz. <del>appointment</del> , resignation, <del>removal, death or otherwise</del>	Resignation
2.	Date of <del>appointment/re-appointment</del> /cessation (as applicable) & <del>term of appointment</del>	May 20, 2026, closing of business hours.
3.	Terms of Appointment	NA
4.	Brief profile (in case of appointment)	NA
5.	Disclosure of relationships between directors (in case of appointment of a Director)	NA
6.	In case of Resignation, mention reason along with Resignation Letter	Due to family commitments. Resignation Letter is attached as <b>Exhibit</b> .



**Richa Singh**

Date: May 01, 2026

To  
Mr. Pankaj Sahni  
Group Chief Executive Officer & Director  
Global Health Limited

Sub: Resignation from the position of General Counsel of the Company

Dear Pankaj,

I hereby tender my resignation from the position of General Counsel of the Company due to family commitments. My last working day shall be close of business hours of May 20, 2026.

I thank you and entire management team for consistent support and guidance during my association with Medanta.

Regards,

  
Richa Singh